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High-density lipoprotein (HDL) is a target in the treatment of athero-
sclerotic cardiovascular disease (ASCVD). There are currently only a
limited number of therapeutic options to increase and enhance the func-
tion of HDL. However, a new exciting therapeutic strategy, high-density
lipoprotein therapy using reconstituted (r)HDL and apolipoprotein
(Apo)A-I mimetic peptides, has recently been developed [1,2]. Recently,
we newly developed apolipoprotein A-I mimetic peptide [Fukuoka
University Apo A-I Mimetic Peptide (FAMP)] and showed that it has an
anti-atherosclerotic effect inmice [3]. rHDL and apo A-Imimetic peptides
in addition to HDL have many pleiotropic effects [4,5], such as anti-
oxidant, angiogenesis, anti-inﬂammatory and anti-thrombotic properties,
in addition to its ability to enhance reverse cholesterol transport.
Therefore, we hypothesized that FAMP also has pleiotropic effects. In
this study, we analyzed whether FAMP has induced endothelial tube
formation with an anti-inﬂammatory effect, and found that these effects
of HDL with FAMP were greater than those of HDL alone.
Matrix gels were purchased from Chemicon International, Inc.
(Temecula, CA). The gels were allowed to polymerize in a 96-well plate
as described previously [6]. Human coronary endothelial cells (HCECs,
Clonetics, San Diego, CA) were seeded and grown under serum-free con-
ditions. In some experiments, HCECs were incubated with the indicated
concentrations of samples for 18 h. Samples were incubated with HDL
with or without FAMP. After cells were washed, EC tube formation was
determined. In addition, HCECswere grown under serum-free conditions
for 24 h and incubated in the presence or absence of different kinds of
samples for 24 h. The secretion of matrix metalloproteinase-2 (MMP-2),
monocyte chemotactic protein-1 (MCP-1) and interleukin-6 (IL-6) in
the medium from HCECs was measured by ELISA kits (R&D Systems,
Minneapolis, MN). Moreover, HCECs were grown under serum-free
conditions for 24 h and added to the indicated concentrations of samples
for 6 h, and a cell proliferation assay was performed using CellTiter 96®
AQueous One Solution Reagent (Promega Corporation, Madison, WI).
As shown in Fig. 1, 50 μg/ml HDL with FAMP dose-dependently led
to the formation of a capillary-like structure on the Matrigel surface.
50 μg/ml HDL with 50 μg/ml FAMP signiﬁcantly promoted tube forma-
tion compared to that seen with 50 μg/ml HDL without FAMP. Since
50 μg/ml HDL with FAMP led to tube formation, we examined the prolif-
eration of HCECs and MMP-2 secretion (Fig. 2AB). 50 μg/ml HDL with
FAMP did not inﬂuence cell proliferation and stimulated the secretion of
MMP-2 from HCECs. Since 50 μg/ml HDL with 50 μg/ml FAMP mosthttp://dx.doi.org/10.1016/j.ijcme.2014.09.001
2214-7624/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access articlinﬂammatory effects under these conditions (Fig. 2CD). The combination
of 50 μg/ml HDLwith 50 μg/ml FAMP signiﬁcantly inhibited the secretion
of MCP-1 and IL-6 compared to that seen with 50 μg/ml HDL alone.
Angiogenesis, the process of postnatal neovascularization, is a
critical component of several human diseases, including ASCVD, cancer,
diabetic microvascular disease and rheumatoid arthritis. We have
reported that HDL and rHDL promoted EC tube formation [6], and this
effect may be beneﬁcial for ischemic diseases, such as ASCVD. In addi-
tion, low concentrations of HDL from healthy donors, but not from
donors with coronary artery disease enhanced endothelial progenitor
cell-mediated tubulogenesis by phosphoinositide 3-kinase/Akt and
endothelial nitric oxide synthase pathways [7]. Cell elongation, migration
and proliferation are key cellular mechanisms that drive angiogenesis. In
the present study, HDL with FAMP promoted tube formation like cell
elongation, without cell proliferation, compared to HDL without FAMP.
FAMP with HDL therapy might be at least in part useful in patients with
ischemic diseases.
MMPs are a family of extracellular endopeptidases that selectively
degrade components of the extracellular matrix. In this study, HDL in-
creased the secretion ofMMP-2 fromHCECs. A previous study described
the interaction between HDL and MMP-2 [8]. HDL blocked oxidized
low-density lipoprotein-induced epidermal growth factor receptor sig-
naling and subsequent MMP-2 activation by inhibiting carbonyl adduct
formation and cellular oxidative stress in smoothmuscle cells [8]. These
results contradict those in the present study, and further research will
be needed to resolve this issue.
Althoughwe previously reported that FAMP signiﬁcantly suppresses
the formation of aortic plaque by enhancing the biological functioning
of HDL in apoE knockout mice [3], we needed to analyze the direct
role of FAMP in this anti-inﬂammatory effect because inﬂammation
plays a pathological role in the progression of atherosclerosis. Mononu-
clear cells receive chemoattractant signals from MCP-1 etc. that lead
them to enter the intima [9]. IL-6 is secreted under stimulation of the
immune response, and acts as a pro-inﬂammatory cytokine. In this
study, HDL with FAMP signiﬁcantly decreased the secretion of MCP-1
and IL-6 compared to that seen with HDL without FAMP. Since FAMP
accelerated the generation of pre-β HDL, which is converted from
mature HDL [3], and since Troutt et al. reported that D-4F dose-
dependently induced pre-β1 HDL formation in vitro in human plasma
and in mice [10], pre-β HDL may have a stronger anti-inﬂammatory
effect.
In conclusion, HDL with our newly developed FAMP evoked pleiotro-
pic effects, such as induction of EC tube formation and anti-inﬂammation.
HDL with FAMP had greater beneﬁcial effects than HDL alone. This bene-
ﬁcial effect induced by FAMP might prevent atherosclerotic ASCVD.
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Fig. 1. Effects of HDL in the absence or presence of the indicated concentrations of FAMPonHCEC tube formation. Images show representative pictures of HCECsplated onMatrigel for 18 h.
A ‘pixel analysis’ of the area of tube formationwas performed as the total number of pixels. Thenumberwas counted in three different areas and the average valuewas determined for each
sample. The untreated control sample (No. 1) was deﬁned as 100% tube formation, and the % increase or decrease in tube formation relative to the control was calculated for each sample.
*p b 0.05 vs. No 1. #p b 0.05 vs. No 4.
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Fig. 2. Effects of HDL in the absence or presence of the indicated concentrations of FAMP on HCEC proliferation (A) and the secretion ofMMP-2 fromHCECs (B). (A) shows the percentage
(%) cell proliferation compared to that in the untreated control sample. *p b 0.05 vs. FAMP(−) + HDL(−). #p b 0.05 vs. 50 μg/ml FAMP + HDL(−). Percentage (%) secretion of MCP-1
(C) and IL-6 (D) from HCECs by HDL in the absence or presence of the indicated concentrations of FAMP. HCECs were grown with HDL in the absence or presence of the indicated
concentrations of FAMP for 24 h before the measurement of MCP-1 and IL-6. *p b 0.05 vs. FAMP (−) + 50 μg/ml HDL.
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